ProCE Banner Activity

Current Status of EGFR Tyrosine Kinase Inhibitor Combination Therapy in the Treatment of Newly Diagnosed EGFR-Mutated Advanced NSCLC

Clinical Thought
Read this expert commentary to gain insights into the rationale and latest clinical evidence for combination strategies with EGFR TKIs for the first-line treatment of EGFR-mutated advanced NSCLC.

Released: December 03, 2021

Expiration: December 02, 2022

No longer available for credit.

Share

Faculty

David Planchard

David Planchard, MD, PhD

Head of Thoracic Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

David Planchard, MD, PhD

Head of Thoracic Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

David Planchard, MD, PhD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, and Samsung.